Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Peer Review reports

Original Submission
2 Apr 2021	Submitted	Original manuscript
6 May 2021	Reviewed	Reviewer Report - Samantha Cruz Rivera
3 Jun 2021	Author responded	Author comments - Maike Wientjes
Resubmission - Version 2
3 Jun 2021	Submitted	Manuscript version 2
Publishing
4 Jun 2021	Editorially accepted
19 Jun 2021	Article published	10.1186/s13063-021-05358-7

Back to article page